UK Biotech Proximagen Raises Record $80 Million ‘Asset Acquisition’ Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
In one of the U.K.’s largest fundraisings, Proximagen avoids paying a discount to its share price. Proceeds will buy CNS pipeline assets.
You may also be interested in...
Upsher-Smith To Buy U.K. Biotech Partner Proximagen For $347 Million
Proposed acquisition mimics other recent M&A deals, like Sanofi/Genzyme, with inclusion of contingent-value rights pegged to success of two clinical candidates.
Lundbeck Invests £10M In CNS-Focused Proximagen
Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.
Lundbeck Invests £10M In CNS-Focused Proximagen
Lundbeck's support for Proximagen comes as biotechs struggle for survival in the high-risk CNS space.